NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06378138 2025-11-21
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3 Recruiting
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown